Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 529.24 USD 1.42% Market Closed
Market Cap: 57.1B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+3%
Revenue
Forecast
+12%
Operating Income
Forecast
+46%
Net Income
Forecast
+53%

Wall Street
Price Targets

REGN Price Targets Summary
Regeneron Pharmaceuticals Inc

Wall Street analysts forecast REGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for REGN is 787.28 USD with a low forecast of 540.35 USD and a high forecast of 1 063.65 USD.

REGN Lowest Forecast
Wall Street Target
540.35 USD
2% Upside
REGN Average Forecast
Wall Street Target
787.28 USD
49% Upside
REGN Highest Forecast
Wall Street Target
1 063.65 USD
101% Upside
Lowest
Price Target
540.35 USD
2% Upside
Average
Price Target
787.28 USD
49% Upside
Highest
Price Target
1 063.65 USD
101% Upside
Regeneron Pharmaceuticals Inc Competitors:
Price Targets
MSB
Mesoblast Ltd
65% Upside
Z
ZBIO
Zenas Biopharma Inc
191% Upside
PAR
Paradigm Biopharmaceuticals Ltd
181% Upside
EXAS
Exact Sciences Corp
32% Upside
MSB
Mesoblast Ltd
65% Upside
Z
ZBIO
Zenas Biopharma Inc
191% Upside
PAR
Paradigm Biopharmaceuticals Ltd
181% Upside
EXAS
Exact Sciences Corp
32% Upside
300841
Chengdu Kanghua Biological Products Co Ltd
40% Upside
S
688373
Shanghai MicuRx Pharmaceutical Co Ltd
21% Downside
P
PRME
Prime Medicine Inc
414% Upside
CSL
CSL Ltd
35% Upside

Revenue
Forecast

Revenue Estimate
Regeneron Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's revenue is 14%. The projected CAGR for the next 3 years is 4%.

14%
Past Growth
4%
Estimated Growth
Estimates Accuracy
-1%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Regeneron Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's operating income is 16%. The projected CAGR for the next 3 years is 11%.

16%
Past Growth
11%
Estimated Growth
Estimates Accuracy
-15%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Regeneron Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's net income is 22%. The projected CAGR for the next 3 years is 7%.

22%
Past Growth
7%
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

See Also

Summary
REGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
REGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
REGN stock valuation using valuation multiples.
Wall Street Estimates
REGN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
REGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is REGN's stock price target?
Price Target
787.28 USD

According to Wall Street analysts, the average 1-year price target for REGN is 787.28 USD with a low forecast of 540.35 USD and a high forecast of 1 063.65 USD.

What is Regeneron Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
4%

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's revenue is 14%. The projected CAGR for the next 3 years is 4%.

What is Regeneron Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
11%

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's operating income is 16%. The projected CAGR for the next 3 years is 11%.

What is Regeneron Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
7%

For the last 8 years the compound annual growth rate for Regeneron Pharmaceuticals Inc's net income is 22%. The projected CAGR for the next 3 years is 7%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 261,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.